Publications

Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

The importance of developing therapies targeting the biological spectrum of metastatic disease

Abstract

Great progress has been made in cancer therapeutics. However, metastasis remains the predominant cause of death from cancer. Importantly, metastasis can manifest many years after initial treatment of the primary cancer. This is because cancer cells can remain dormant before forming symptomatic metastasis. An important question is whether metastasis research should focus on the early treatment of metastases, before they are clinically evident ("overt"), or on developing treatments to stop overt metastasis (stage IV cancer). In this commentary we want to clarify why it is important that all avenues of treatment for stage IV patients are developed. Indeed, future treatments are expected to go beyond the mere shrinkage of overt metastases and will include strategies that prevent disseminated tumor cells from emerging from dormancy.

Type Journal
ISBN 1573-7276 (Electronic) 0262-0898 (Linking)
Authors Zijlstra, A.; Von Lersner, A.; Yu, D.; Borrello, L.; Oudin, M.; Kang, Y.; Sahai, E.; Fingleton, B.; Stein, U.; Cox, T. R.; Price, J. T.; Kato, Y.; Welm, A. L.; Aguirre-Ghiso, J. A.; Board Members of the Metastasis Research, Society
Responsible Garvan Author Dr Thomas Cox
Publisher Name CLINICAL & EXPERIMENTAL METASTASIS
Published Date 2019-08-31
Published Volume 36
Published Issue 4
Published Pages 305-309
Status Published in-print
DOI 10.1007/s10585-019-09972-3
URL link to publisher's version https://www.ncbi.nlm.nih.gov/pubmed/31102066